News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website


A retrospective single institutional analysis of bevacizumab and chemotherapy versus non-bevacizumab treatments for recurrent glioblastoma.


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=35943

Posted on: 10/04/2008

A retrospective single institutional analysis of bevacizumab and chemotherapy versus non-bevacizumab treatments for recurrent glioblastoma.

Sub-category:

Central Nervous System Tumors

Category:

Central Nervous System Tumors

Meeting:

2008 ASCO Annual Meeting

 Printer Friendly

 E-Mail Article

Abstract No:

2023

Citation:

J Clin Oncol 26: 2008 (May 20 suppl; abstr 2023)

Author(s):

P. Nghiemphu, C. Graham, W. Liu, T. Than, A. Lai, R. Green, R. M. Elashoff, T. F. Cloughesy

Abstract:

Background: Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, has been shown to be effective in the treatment of recurrent glioblastoma in combination with chemotherapy compared to historical controls but not in randomized trials. Methods: We conducted a retrospective analysis of all patients treated at our institution for a recurrent glioblastoma to compare patients who received bevacizumab versus a control group of patients. We compared progression free survival (PFS) and overall survival (OS) between the two groups, and also compared these factors based on the age and performance status within each group. We also analyzed the impact of bevacizumab on quality of life by comparing change in performance status. Results: We identified 44 patients who received bevacizumab, and 79 patients who have not been treated with bevacizumab. There is a statistically significant improvement in PFS in the bevacizumab treated group, but only a trend toward better survival. Patients of older age (>50) and poor performance status (KPS<80) have significantly better PFS when treated with bevacizumab, and bevacizumab-treated older patients have significantly increase OS. Patients treated with bevacizumab also maintained their functional status longer than the control group. Conclusions: Bevacizumab in combination with chemotherapy can be a more effective treatment for recurrent glioblastoma and warrants further randomized prospective studies to determine its effect on survival. Bevacizumab also has more effect in those with older age and might reflect biological differences in glioblastoma in different age groups, and biological correlates should also be considered.

  Bev Control p value
No 44 79  
Age
KPS
54
82
55
82
0.86
0.8
Recurrence (%)      
  1st
  2nd
  3rd
50
32
18
100
0
0
 
PFS (mos)      
  all (n)
  age <50 (n)
  age >50 (n)
  KPS >80 (n)
  KPS <80 (n)
4.25 (44)
4.01 (15)
4.60 (29)
3.83 (24)
4.60 (20)
1.82 (79)
2.01 (28)
1.87 (51)
1.84 (36)
1.87 (43)
0.01
0.85
0.0002
0.16
0.04
OS (mos)      
  all
  age <50
  age >50
  KPS >80
  KPS <80
9.01
10.83
8.31
9.22
9.01
6.11
6.88
6.11
8.05
4.74
0.08
0.74
0.02
0.61
0.08
Time to KPS change (days) 252 120 0.006

 

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740